Earnings call transcript: Siemens Healthineers Q2 2026 sees stock plunge amid Diagnostics woes

FierceBiotechFrom drug development to M&A, Big Pharmas showcase AI’s ‘measurable impact’

Lonza NewsBMS Licenses SYNtecan Linker-Payload Platform from Lonza - Contract Pharma

Endpoints NewsAtara, Pierre Fabre's cell therapy to get another shot at FDA approval

FierceBiotechInsulet boosts guidance in Q1 update as it grapples with recall saga

PharmaVoiceLilly, Gilead lead pharma’s M&A boom

LabiotechThe rise of trispecific antibodies: Biopharma’s next big bet after bispecifics

Endpoints NewsPennsylvania sues AI chatbot company for posing as a licensed doctor

Novo NordiskNovo Nordisk faces competition from Canada compounders - medwatch.com

Endpoints NewsAngelini fortifies neurology portfolio with $4.1B buyout of Catalyst Pharma

Eli LillyPharma Pulse: GLP-1 Momentum Builds While Lilly Expands Genetic Medicine Manufacturing - Pharmaceutical Commerce

Siemens HealthineersWeak Diagnostics segment weighs heavily on Siemens Healthineers - marketscreener.com